title: Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
abstract: When using molecularly targeted agents (MTAs), oncologists and patients face new and sometimes unexpected toxicities. Though ocular adverse events (OAEs) are not uncommon with chemotherapy, they are rarely severe or dose limiting. Ocular toxicity profile may differ with MTAs, indeed severe and dose limiting toxicities have been described with targeted therapies currently under investigation. Our study aimed to review OAEs experienced with MTAs approved in solid tumours. This review revealed that many OAEs, frequent and potentially severe, exist and concern most MTAs. The suggestion is prompt referral of patients with severe pain and/or visual impairment to the ophthalmologist since these symptoms can be associated with potentially severe OAE and need ophthalmic assessment. Oncologists must be aware of such events and their potential severity for better treatment and better diagnosis in daily practice as well as in clinical trials.
authors.affiliation: Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Huillard
authors.affiliation: Department of Ophthalmology, Institut Curie, Paris, France.
authors.forename: Silvin
authors.initials: S
authors.lastname: Bakalian
authors.affiliation: Department of Ophthalmology, Institut Curie, Paris, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Levy
authors.affiliation: Department of Ophthalmology, Institut Curie, Paris, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Desjardins
authors.affiliation: Department of Ophthalmology, Institut Curie, Paris, France.
authors.forename: Livia
authors.initials: L
authors.lastname: Lumbroso-Le Rouic
authors.affiliation: Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France.
authors.forename: Simona
authors.initials: S
authors.lastname: Pop
authors.affiliation: Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France.
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Sablin
authors.affiliation: Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France; Institut Curie/INSERM U900, Paris, France. Electronic address: christophe.letourneau@curie.net.
authors.forename: Christophe
authors.initials: C
authors.lastname: Le Tourneau
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D005128:Eye Diseases / Q000139:chemically induced*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects* / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Eye; Molecularly targeted agents; Ophthalmology; Systematic review; Toxicity; Treatment outcome